West Pharmaceutical Services, Inc.

WST · NYSE · Stock · Healthcare
$376.01
+1.13% today
Delayed price,

What West Pharmaceutical Services does

West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging products. This segment also provides drug containment solutions in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. This segment primarily serves pharmaceutical, diagnostic, and medical device companies. It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors. West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.

Key facts

Sector
Healthcare
Industry
Medical Instruments & Supplies
Market cap
$26.46B
P/E (ttm)
48.3
Forward P/E
37.6
Dividend yield
0.24%
Beta
1.13
Profit margin
17.0%
Employees
10,800
Headquarters
Exton, PA, United States
Exchange
NYSE

Performance

1 Month
+3.8%
3 Months
+5.0%
6 Months
+37.4%
1 Year
+39.0%
5 Years
-15.1%
$223.8352-week range$386.00
Biggest setback — last 12 months
-22.3%
20 Oct 2025 → 26 Jan 2026
Fell from $297.47 to $231.12 — its sharpest sustained decline this year.
Biggest run-up — last 12 months
+62.7%
26 Jan 2026 → 14 Oct 2026
Ran from $231.12 to $376.01 — its strongest sustained advance this year.

Price outlook — trend & volatility model

▲ Trend: Uptrend
Price is above its 20-, 50- and 200-day averages, each stacked above the next — a classic technical uptrend structure.
HorizonBear case (−1σ)Base caseBull case (+1σ)
1 Month$344.74 (-8.3%)$376.01$410.12 (+9.1%)
3 Months$323.51 (-14.0%)$376.01$437.03 (+16.2%)
6 Months$303.97 (-19.2%)$376.01$465.12 (+23.7%)
12 Months$278.34 (-26.0%)$376.01$507.95 (+35.1%)
Statistical, not machine-learning: a random-walk (no assumed drift) volatility model built from this ticker's own realized price history, plus a purely descriptive moving-average trend read. Illustrative only — not a price target and not financial advice. The bear and bull cases sit one standard deviation (1σ) below and above today's price, a range that covers about 68% of the outcomes the model treats as plausible, not a 68% chance of either case. Annualized volatility used: 30.1%, blended from this ticker's own 3-month and 1-year realized price history. Base case is deliberately flat — this quantifies a possible range, not a directional prediction. See the full model, including wider (≈95%) bands →

Comparable companies

Recent headlines

Recent insider activity

Sold 989 shares at $312.07 — Campbell Shane Alden, SVP, Proprietary Segment · 2026-05-14
Acquired 791 shares — Pucci Paolo, Director · 2026-05-06
Source: SEC Form 4 filings. An "acquired" entry with no price is typically a stock award or option exercise rather than an open-market purchase. Search all insider trades →

Learn the basics

Prices and company data are delayed reference figures from public sources (Yahoo Finance, SEC EDGAR) and may be inaccurate or out of date. This page is informational only — it is not investment advice or a recommendation to buy or sell any security. Past performance does not indicate future results.